CN101433509A - 野菊花萃取物及其在抗皮肤老化化妆品中的应用 - Google Patents
野菊花萃取物及其在抗皮肤老化化妆品中的应用 Download PDFInfo
- Publication number
- CN101433509A CN101433509A CNA2008100907850A CN200810090785A CN101433509A CN 101433509 A CN101433509 A CN 101433509A CN A2008100907850 A CNA2008100907850 A CN A2008100907850A CN 200810090785 A CN200810090785 A CN 200810090785A CN 101433509 A CN101433509 A CN 101433509A
- Authority
- CN
- China
- Prior art keywords
- wild chrysanthemum
- chrysanthemum extract
- skin
- cosmetics
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000035851 Chrysanthemum leucanthemum Species 0.000 title claims abstract description 80
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 title claims abstract description 80
- 239000000284 extract Substances 0.000 title claims abstract description 80
- 239000002537 cosmetic Substances 0.000 title claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 230000037303 wrinkles Effects 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 238000001914 filtration Methods 0.000 claims abstract description 10
- 239000006071 cream Substances 0.000 claims abstract description 8
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- 241000628997 Flos Species 0.000 claims description 27
- 239000002552 dosage form Substances 0.000 claims description 6
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 230000035764 nutrition Effects 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 abstract description 18
- 102000008186 Collagen Human genes 0.000 abstract description 18
- 229920001436 collagen Polymers 0.000 abstract description 10
- 230000032683 aging Effects 0.000 abstract description 6
- 230000008929 regeneration Effects 0.000 abstract description 6
- 238000011069 regeneration method Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 239000012153 distilled water Substances 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 abstract description 4
- 238000010438 heat treatment Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract 2
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000006210 lotion Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 27
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 108010050808 Procollagen Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000000787 lecithin Substances 0.000 description 8
- 229940067606 lecithin Drugs 0.000 description 8
- 235000010445 lecithin Nutrition 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 238000007805 zymography Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 230000008033 biological extinction Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000013112 stability test Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 5
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- -1 hexadecanol-K Chemical compound 0.000 description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000012177 spermaceti Substances 0.000 description 3
- 229940084106 spermaceti Drugs 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 241000723353 Chrysanthemum Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 235000005135 Micromeria juliana Nutrition 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 240000002114 Satureja hortensis Species 0.000 description 2
- 235000007315 Satureja hortensis Nutrition 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QBYFCXBVWQQXFH-UHFFFAOYSA-N acaciin Natural products COc1ccc(cc1)C2=CC(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4OC6OCC(O)C(O)C6O)cc3O2 QBYFCXBVWQQXFH-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- IECBDTGWSQNQID-JGVFFNPUSA-N (1r,5s)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-7-one Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2=O IECBDTGWSQNQID-JGVFFNPUSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000721329 Chrysanthemum boreale Species 0.000 description 1
- 235000008642 Chrysanthemum boreale Nutrition 0.000 description 1
- IECBDTGWSQNQID-UHFFFAOYSA-N Chrysanthenon Natural products CC1=CCC2C(C)(C)C1C2=O IECBDTGWSQNQID-UHFFFAOYSA-N 0.000 description 1
- IECBDTGWSQNQID-SFYZADRCSA-N Chrysanthenone Natural products CC1=CC[C@H]2C(C)(C)[C@@H]1C2=O IECBDTGWSQNQID-SFYZADRCSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- WWUVLNPEWUTCEI-KRWDZBQOSA-N Flowerone Chemical compound C1=C(O)C(CC=C(C)C)=CC([C@H]2OC3=C(O)C(O)=CC(O)=C3C(=O)C2)=C1 WWUVLNPEWUTCEI-KRWDZBQOSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241001093152 Mangifera Species 0.000 description 1
- XZTYGFHCIAKPGJ-UHFFFAOYSA-N Meclofenoxate Chemical compound CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 XZTYGFHCIAKPGJ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 241001354471 Pseudobahia Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241001400675 Sympodium Species 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013142 basic testing Methods 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- YVBUWVMMORNHHZ-UHFFFAOYSA-N flowerone Natural products CC(=C)CCc1cc(ccc1O)C1CC(=O)c2c(O)cc(O)c(O)c2O1 YVBUWVMMORNHHZ-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- SZQWAXGDCUONOB-RJRCOPBWSA-N handelin Chemical compound C([C@@]1(C(=O)O[C@@H]2[C@H]3C(C)=CC[C@H]3[C@](C)(O)C[C@@H]([C@@H]12)OC(=O)C)[C@]1(C)C=C2)[C@]22[C@@H]1[C@@H]1OC(=O)C(=C)[C@@H]1CC[C@@]2(C)O SZQWAXGDCUONOB-RJRCOPBWSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 229960003442 meclofenoxate Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- KJCLYACXIWMFCC-UHFFFAOYSA-M sodium;5-benzoyl-4-hydroxy-2-methoxybenzenesulfonate Chemical compound [Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 KJCLYACXIWMFCC-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 1
- 238000003210 sulforhodamine B staining Methods 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- DSNIKOZTDZBWKD-XMNJDQQWSA-N yejuhua lactone Chemical compound O([C@H]1C2C[C@H]([C@@](C3C1C(=CC3)C)(C)O)OC(=O)C)C(=O)C2(C1(C)C=C2)CC22C1[C@H]1OC(=O)C(=C)C1CC[C@@]2(C)O DSNIKOZTDZBWKD-XMNJDQQWSA-N 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
Abstract
本发明的野菊花萃取物是这样制得的：取野菊花与水的重量比例为1∶20，将野菊花切碎后加入经过三道净化的蒸馏水中，加热至90－110℃，保持该温度连续煮1.5－3个小时，过滤去除残渣后，滤液在60℃条件下减压浓缩至原来水体积的十分之一，即得具有活性成分的野菊花萃取物。精草提取物作为有效活性成分在抗衰老、改善皮肤皱纹的营养化妆水、膏霜、精华液等化妆品中得应用。本发明的野菊花萃取物，具有显著的促进细胞再生，促进胶原蛋白的合成，有效吸收紫外线，抗皮肤老化，显著改善皱纹的功效，同时与配方结合的稳定性好，在改善皮肤皱纹，抗衰老方面具有良好的效果。
Description
技术领域
本发明涉及一种植物提取物及其应用领域，具体为野菊花萃取物及其在抗皮肤老化化妆品中的应用。
背景技术
随着社会经济的发展、生存环境的改善，人们对提高生命质量越来越重视，延缓衰老、健康长寿成为普遍而迫切的社会需求。然而人体衰老的现象在目前还是人体不可避免的生理规律。随着年龄在增长，身体上的皮肤，特别是脸部皮肤会慢慢的失去原有的弹性，原有的皮肤光泽，变得松弛，出现皱纹等。据研究，人们，特别是女性在25岁之后，皮肤就开始出现衰老现象。这给人们带来了不少痛苦和心理压力。
目前，市面上推出了不少相应的抗衰老口服保健品和抗衰老功能性化妆品。据统计，其中抗衰老功能性化妆品就占整个化妆品市场份额将近50％。目前抗衰老化妆品中添加的活性物有以下两类：1、抗衰老化学药物，如包括抗氧化剂(如维生素E，维生素C，氯酯醒、抗氧化酶(SOD等)、免疫调节剂(如胸腺素、PHA等)、生化制剂(如核酸、唾液酸等)、防大脑衰老剂(如脑复康、益康宁等)等。2、抗衰老天然药物，如抗衰老植物药物(如人参、刺五加、红景天、枸杞等)、抗衰老动物药(如鹿茸、紫河车、蜂蜜、蛤蚧等)、抗衰老矿物药(如麦饭石、阳起石等)等等。以上的抗衰老活性物在延缓皮肤衰老，改善皮肤弹性的方面起到了一定的效果，但是远没有能满足人们深切的需求。其中天然植物药物提取物由于具有系统的理论体系、悠久的临床应用，副作用小，效果明显等优点，现在是应用和研究的重点。
野菊花是多年生草本，高达1m。茎基部常匍匐，上部多分枝。叶互生，卵状三角形或卵状椭圆形，长3～9cm，羽状分裂，裂片边缘有锯齿，两面有毛，下面较密；叶柄下有明显的假托叶。头状花序直径2～2.5cm，排成聚伞状；总苞半球形，总苞片4层，边缘膜质，外层椭圆形；花小，黄色，边缘舌状，先端3浅裂，雌性；中央为管状花，先端5裂，两性。花期9～11月，果期10～11月。其性状为：花序呈类球形，直径0.3～1cm，棕黄色；总苞由4～5层苞片组成。舌状花一轮，黄色，皱缩卷曲；管状花多数，深黄色；体轻；气芳香，味苦。据检测，野菊花含有菊甙、黄酮类、蛋白质、氨基酸、脾嘌呤、胆碱、水苏碱、醣类、酯类、鞣质、维生素B1、叶绿素、挥发油等众多成分，其中挥发油中含菊醇(chrysol)、菊酮(chrysanthenone)、α-蒎烯、樟脑、龙脑、樟烯等，尚含野菊花内酯(yejunualactone)、野菊花素A(artoglasin-A)、刺槐甙(acaciin)、蒙花甙(linarin)、菊甙、木犀草素等。现代医学研究表明，野菊花其性味苦甘微寒，具有很广的抗菌谱，对大肠杆菌、金黄色葡萄球菌、甲型及乙型链球菌等有很强的抑杀作用，同时还具有散风清热、消炎解毒、平肝明目、祛痰止咳、理气止痛、凉血止血、抗菌、抗病毒等功效，可治疗风热感冒、头痛头昏、心胸烦热、咽喉肿痛、眩晕耳鸣、流行性感冒以及高血压、高血脂、偏头痛、冠心病、乳腺炎、扁桃体炎、老年慢性支气管炎、鼻衄、毒蛇咬伤、蜂螫虫咬、疗疮、无名肿毒、扭伤、外伤出血等疾病。野菊花在清热解毒，消炎，消肿等药品和饮料行业中应用广泛，但作为单一萃取物的活性物在抗皮肤老化功能性化妆品方面的应用，目前均没有发现到相应的文献记载和报道。
发明内容
本发明是经过对数十种具有清热解毒药性、适用于强烈阳光及紫外线的，具有成长特性的植物为主中草药的研究筛选，目的是提供一种具有细胞再生功能，能有效抵抗皮肤老化，显著改善皱纹的野菊花萃取物及其在抗皮肤老化化妆品中的应用。
本发明的野菊花萃取物是这样制得的：取野菊花与水的重量比例为1：20，将野菊花切碎后加入水中，加热至90-110℃，保持该温度连续煮1.5-3个小时，过滤去除残渣后，滤液在60℃条件下减压浓缩至原来水体积的十分之一，即得具有活性成分的野菊花萃取物。
所述的野菊花萃取物制造的优选方案是：取野菊花与水的重量比例为1：20，将野菊花切碎后加入水中，加热至100℃，保持该温度连续煮2个小时，过滤去除残渣后，滤液在60℃条件下减压浓缩至原来水体积的十分之一，即得具有活性成分的野菊花萃取物。
所述的水为经过三道净化的蒸馏水。
所述的野菊花优选北野菊。
所述野菊花萃取物作为有效活性成分在抗衰老、改善皮肤皱纹的功能性化妆品中应用。
所述的野菊花萃取物在化妆品中用量可以占整个化妆品重量的0.0001～90％。
所述的野菊花萃取物可以制成营养化妆水、膏霜、精华液及可溶化剂型的柔软化妆水等化妆品。
本发明的野菊花萃取物，具有显著的促进细胞繁殖，促进胶原蛋白的合成，有效吸收紫外线，抗皮肤老化，显著改善皱纹的功效，同时与油脂、乳化剂等原料的匹配稳定性好。野菊花萃取物可以应用于营养化妆水、膏霜、精华液等功能性化妆品中，在改善皮肤皱纹，抗皮肤老化方面具有良好的效果，满足了很大部分人延缓皮肤衰老的需求，具有广阔的市场。
附图说明
图1为野菊花萃取物的细胞增值效果图；
图2为野菊花萃取物的低浓度细胞增值效果图
图3为野菊花萃取物的胶原蛋白合成效果图；
图4为野菊花萃取物在酶谱法(zymograph)中的活性效果图；
图5为野菊花萃取物在UV吸光光谱图；
图6为野菊花萃取物与不饱和卵磷脂结合应用的配方和工艺图；
图7为野菊花萃取物与饱和卵磷脂结合应用的配方和工艺图；
图8为野菊花萃取物与非离子表面活性剂结合应用的配方和工艺图；
图9为野菊花萃取物与不饱和卵磷脂、饱和卵磷脂以及非离子表面活性剂组成物质特性表；
图10为野菊花萃取物与不饱和卵磷脂、饱和卵磷脂以及非离子表面活性剂组成物质尺寸分布表；
图11为野菊花萃取物与饱和卵磷脂以及非离子表面活性剂组成物质稳定性测试表；
图12为野菊花萃取物与不饱和卵磷脂组成物质稳定性测试表；
图13为野菊花萃取物的悬浮液配方和生产工艺图；
图14为野菊花萃取物悬浮液的稳定度测试表；
图15为野菊花萃取物的膏霜配方和生产工艺图；
图16为野菊花萃取物的膏霜制品的稳定度测试表。
具体实施方式
以下结合附图和具体实施例对本发明进行详细的说明。
野菊花萃取物是这样制得的：取野菊花与水的重量比例为1：20，将野菊花切碎后加入水中，加热至90-110℃，保持该温度连续煮1.5-3个小时，过滤去除残渣后，滤液在60℃条件下减压浓缩至原来水体积的十分之一，即得具有活性成分的野菊花萃取物。
实施例1
取野菊花与水的重量比例为1：20，将野菊花切碎后加入水中，加热至100℃，保持该温度连续煮2个小时，过滤去除残渣后，滤液在60℃条件下减压浓缩至原来水体积的十分之一，即得具有活性成分的野菊花萃取物。
实施例2
取野菊花20克，切碎后加入至400ml的蒸馏水中，加热至100℃，保持在该温度连续煮2个小时，过滤去除残渣后，滤液在60℃条件下减压浓缩处理至剩下40ml后得具有活性成分的野菊花萃取物。
为了避免受到重金属等毒害物质的污染，影响野菊花萃取物内部活性物的活性，所用的水最好是经过三道净化的蒸馏水：第一步，活性炭去杂质，第二步，离子交换，第三步，高精密度过滤。过滤的滤芯为1100目。野菊花优选北野菊(Chrysanthemum Boreale Flower)。
抗皮肤老化效果和配方稳定性分析试验
为了证明提取的野菊花萃取物有显著促进细胞再生，促进合成胶原蛋白的合成，能显著改善皮肤皱纹，抗击紫外线的功效，发明人作了大量的研究和试验。
一、皱纹改善效果试验：
主要通过皮肤纤维亚细胞(Normal human fibroblast)、角质形成细胞(Normal human keratinocyte)、角质形成细胞株(Immortalized humankeratinocytes)等皮肤细胞进行皱纹改善效果试验。
1、细胞增殖试验(cell proliferation Assay)
试验原理：作为皱纹改善效果试验当中的基础试验，通过添加试验物质，利用增值的细胞数，通过色素或者放射性同位素进行测量。
测定方法可以通过[3H]-Thymidne Uptake Assay、Neutral Red Uptakeassay、MTT assay、SRB assay等方法，当中通常执行MTT assay进行试验。MTT方法步骤如下：
在体外培养盒T-75flask中培养的成纤维细胞因子HNF(Normal HumanFibrolast)用1PBS溶液清洗2-3次后，通过1胰酶细胞消化液(trypsin-EDTA)滴定附着的细胞后，在1500rpm条件下离心分离5分钟左右集合细胞。离心机为德国Heraeus公司的Labofuge 400R((Heraeus，Labofuge 400R))。离心分离后，去除上层液，在晶片(pellet)中添加10ml的含有5％FBS的DMEM溶液，搅拌均匀。通过血球计数板(Heamacytometer)测量细胞数量，将2103ea/well的细胞培养皿面积的细胞在96孔细胞培养皿中各配分200ul。在37度5％ C02中进行培养，待细胞培养皿(well)面积中约50％程度的细胞生长后，更换新的含有2％FBS的DMEM溶液，将试验物质按照浓度分别转录(duplicate)添入细胞培养皿中，在37度5％ CO2中分别按照时间段培养细胞。将MMT((3-(4，5-dimethylthiazol-2-yl)2，5-diphenyl tetrazolium bromide、sigma)溶解在PBS中，按照2mg/ml溶解后，冷藏保管使用即可。在各细胞培养皿(well)中将MMT试料(2mg/ml in pbs)培养基(volume)的10％(20ul)进行处理，再培养2小时后，去除上层液，放入150ul二甲基亚砜(DMSO)，充分搅拌后放入0.04N HCL(in acid-isopropanol)100ul充分搅拌。所有上述步骤结束后，通过ELLSA leader(Quant、Bio-Tek instrument INC)在560nm条件下进行测量(相关波长为650nm)。
测量结果如图1所示，1ppm浓度的野菊花萃取物使人体成细胞增殖为原来未用野菊花萃取物的124.82％，10ppm浓度的野菊花萃取物使人体成细胞增殖为原来未用野菊花萃取物258.27％。可见，野菊花具有120％～260％的高效能性，浓度越大，细胞增值效果越明显。为了验证此效能，将浓度再度降低进行实验，结果如图2所示，证明野菊花具有很高的细胞再生效果。
2、胶原蛋白合成性能试验(Collagen synthesis Assay)
方法及原理：通过野菊花萃取物，测量合成的胶原蛋白的量。
用ELISA法通过胶原蛋白质的procollagen c-末梢抗认知的抗体测量胶原蛋白生成量的方法，可以通过试纸KIT(Takara MK101、procollagen Type Ic-peptide ELA kit)进行如下试验。
试验顺序：
1.免疫反应(immunological reaction)：(1)将100ul的POD抗体(antibody-PODconjugate sol)连接液加入第1抗体覆盖孔细胞培养皿(1st antibody-coatedwell)中；(2)添加20ul试样及标准液；(3)混合后用金属箔片封装(Mixing、Sealing with foil)(4)在37℃的条件下培养3个小时(Incubation at 37oC for3hours)；
2.去除反应液；
3.通过PBS清除3次剩余的PBS；
4.加入100ul酶标二抗(kit内有)，反应；
5.室温反应15分钟；
6.加入100ul终止液(kit里有，为1N硫酸)，终止显色；
7.轻轻摇晃后在酶标仪上读取(450nm处的OD值)；
8.读取collagen assay值。
试验结果如图3所示，1ppm浓度的野菊花萃取物能使胶原蛋白得合成能力增加近6％；10ppm浓度的野菊花萃取物能使胶原蛋白得合成能力增加近13％；100ppm浓度的野菊花萃取物能使胶原蛋白得合成能力增加近6％。总的来说，野菊花萃取物能使人体皮肤胶原蛋白合成能力增加约10％。
3.采用酶谱法(Zymography)分析皱纹改善效果试验
野菊花的酶谱法细胞外基质(Zymograph Extracellular matrix)的主要成分—利用胶原蛋白(collagen)分解的活性蛋白质分解酵素中的基质金属蛋白酶(matrix metalloproteinase(MMP)试验。
蛋白质的抗原-抗体反应产生的胶原蛋白的发现量的确认方法，可分为western blot及immuno assay方法。这些方法不仅需要进行观察(MMP-1)，而且还需要确认蛋白质的活性，因此采用了酶谱法(zymography)试验方法(MMP-2)。即在成纤维细胞(Normal Human Fibroblast)中分离UVA后，通过确认UVA的前胶原蛋白(procollagen)的减少及基质金属蛋白酶(MMP)的增加来检验它们对萃取物的抑制效果。具体操作可以参看invitrogen公司的Novex pre-cast gel说明书。
所使用的试纸：
10％ Zymogram(0.1％ gelatin)Gel
Novex Tris-Glycine SDS Running Buffer(10X)500ml、Cat.No.LC2675
Novex Tris-Glycine SDS Sample Buffer(2X)20ml、Cat.No.LC2676
Novex Zymogram Renaturing Buffer(10X)500ml、Cat.No.LC2670
Novex Zymogram Developing Buffer(10X)500ml、Cat.No.LC2671
试验方法
1.调节相同的蛋白质(protein)量并保证可移走(loading)，混合与样品相同的体积的sample buffer(2X)缓冲溶液，在室温中放置10分钟。
2.利用pre-casting gel，移放至细胞培养皿中。在125V的电压中凝胶体电泳(gel running)约90分钟左右。在Novex Zymogram Renaturing Buffer(1X)100ml中轻轻摇晃凝胶体(gel)，放置约30分钟左右。用Novex ZymogramDeveloping Buffer(1X)更换，充分搅拌约1小时左右。更换为新的Developingbuffer后，在37℃中放置一夜。用考马斯亮蓝R—250(Commassie Blue R-250solution(dye 50mg、MeOH 22.5ml、DIW 22.5ml、glacial acetic acid 5ml))进行染色。用脱色液(destaining solution(MeOH5ml、glacial aceticacid 5ml、Diw 40ml))进行脱色处理。干燥试剂盒，注意避免气泡出现，充分进行干燥。
试验结果如图4所示，野菊花虽然在酶谱法中的活性看似有效果，但是在基质金属蛋白酶—1(MMP-1)或前胶原蛋白(procol lagen)中则没有任何效果。可以确认野菊花萃取物的效果
从多次实验观察到的情况来看，可以确认，野菊花萃取物具有活性，前胶原蛋白(procol lagen)也从蛋白质的发现量的差异，由基质金属蛋白酶—1(MMP-1)一起通过Western blotting法实验，带状(Band)太模糊，所以只能用扫描的方法来看。但是可以证明野菊花在UVA中可以抑制前胶原蛋白(procol lagen)的减少效果。这和通过UV吸光灯看到的结果相似。
二、紫外线试验
分析方法
(1).将试样用适量水定量稀释(最大吸收光峰值在1以内的吸光度范围捡出的浓度予以确定)
(2).采用波谱图谱(UV—vis spack trum)(日本岛津SHIMADZU UV-1601)进行分析
(3).吸收波长为200—500nm.
试验结果如图5所示，野菊花萃取物在10ppm浓度中显现出了吸光特性。最大吸光波长出现在265-285nm。野菊花以峰的形态，在326nm中显现出了吸光峰值。因此，野菊花萃取物具有自行吸收UV的吸光特性。
三、野菊花萃取物与不饱和卵磷脂结合应用
采用卵磷脂(Phosphatidyl Choline(PC))的含量为75％的不饱和卵磷脂(LIPOIDS 75(LIPOID公司生产))进行试验。可在常温进行生产，配方和生产工艺如图6所示：将不饱和卵磷脂和鲸蜡磷酸脂加入乙醇中，然后加入2，6-二叔丁基对甲酚在常温下溶解，均质1分钟形成油相，将乙二胺四乙酸二钠和维他命C磷酸脂钠加入去离子水中溶解，然后加入野菊花萃取物形成水相，将油相加入水相中，通过Agi-Mixer或HOMOMIXER以8000psi进行自由乳化，反复3次，然后再用fluidizer进行生产。
四、野菊花萃取物与不饱和卵磷脂结合应用
采用卵磷脂(PC)的含量约为70％，磷脂酰乙醇胺(phosphatidylethanolamine(PE))的含量约为10％的饱和卵磷脂(LIPOID S 75-3)进行试验。卵磷脂(PC)的含量为70％的水添加卵磷脂为自然界中发现的卵磷脂，在水溶液中具有黏性的片层结构(Lamella)的特点。配方和生产工艺如图7所示：大豆卵磷脂(饱和)与鲸蜡磷酸脂加入乙醇中，然后分别加入2，6-二叔丁基对甲酚和2，6-二叔丁基对甲酚在60度下完全融解后，以转速7000rpm均质1分钟，通过HOMOMIXER进行自由乳化，形成油相；将乙二胺四乙酸二钠和维他命C磷酸脂钠加入去离子水中溶解，然后加入野菊花萃取物形成水相，将油相加水相在70℃，以10000psi均质3次，获得象牙色乳化物。
为了溶解卵磷脂，需在60度以上进行加热，但是由于可获得较高的透明度，因为卵磷脂的溶解温度为55度。
五、野菊花萃取物与非离子表面活性剂的混合(NSV)
在含有神经酰胺及胆固醇的配方体系中，于非离子表面活性剂的混合制品中加入野菊花萃取物。具体配方及生产工艺流程如图8所示：将胆固醇/神经酰胺加热至100℃，完全溶解，将鲸蜡磷酸脂、甘油、丙二醇和去离子水加热60℃后缓慢的投入加热的胆固醇/神经酰胺中，然后加入野菊花精华，最后加入加热至60℃的防腐剂和香精，以7000rpm转速均质5分钟，最后为用德国的microfluidizer微乳化3次。
因为，0NSV base中含有胆固醇及神经酰胺成分，因此在高温中必须进行溶解才能够正常使用。虽然不是完全的角质层组成物质，不过可以确保充分的保湿效果。制作Pre-emulsion，进行3次M/F之后，完成剂型。相同地在这里将NSV调为10％以上时，黏度增高，最终会以渚哩的形态出现，因此不推荐。完成的剂型虽然不知道是否稳定，但是可以知道，在乳化的剂型里也可以出现渚哩状的形态。
以上的不饱和型、饱和型和非离子型NSV的整体测试结果：
①、组成物质的特性，如图9所示，为蒸馏水的PH值为7.02的物质特性表。
②、组成物粒子大小，可通过Submicro Particle Sizer(NICOMP 380、Particle sizing Systems，Inc.)在2％的水溶液状态中进行测量；如图10所示，为各个尺寸的高斯(Gautian)分布，可见，不饱和形态的尺寸最小，剩余部分具有更大的尺寸趋向。
③、温度稳定性，如图11所示，NSV型和饱和型在45度、37度以及30度下60天内都具有良好的稳定度，如图12所示，不饱和型的稳定度效果比较差。
六、野菊花萃取物在悬浮液中的稳定度试验
配方和生产工艺如图13所示，制作过程：将乙二胺四乙酸二钠、二苯甲酮—5、甘油、1，3—丁二醇、透明质酸钠和海藻糖加入去离子水中完全融解，将野菊花萃取物加入以上溶液中完全融解；将POE(60)氢化蓖麻油、尼泊金甲酯、维他命E醋酸酯、环聚二甲基硅氧烷和香精加入乙醇在30℃中完全融解，然后缓慢的加入到以面配置的水相溶液中，过滤后，将产品放置在恒温槽中保管。
从外观看，含野菊花萃取物0.1％、1％和10％的悬浮液的悬浮度依次为P33>P32>P31，可看出其悬浮度较高。
可溶性稳定度如图14所示，变味-采用与原有香味相同的香，变色、悬浮度变化-冷藏及45度进行比较，在各个温度范围内的稳定度无变化。
七、野菊花萃取物在乳化剂型配方体系中的稳定度试验
配方和生产工艺如图15所示，制作过程：首先将硬脂酸、十六醇-K、单硬脂酸甘油酯及聚氧乙烯(100)硬脂酸酯、尼泊金甲酯、尼泊金丙酯、自乳化单甘酯、失水山梨醇倍半油酸酯和聚癸酸在70～75℃下混合完全溶解；将辛酸十六酯、三酸甘油酯、二甲基硅油、芒果油、维他命E醋酸酯和环聚二甲基硅氧烷混合溶解，然后加入以上混合溶解的溶液，在7000rpm下均质3分钟，进行第一次硫化；将乙二胺四乙酸二钠、卵磷脂、聚丙烯酸钠、聚丙烯酸酯、甘油、汉生胶、蔗糖酯和杰马115加入去离子水中溶解，然后将以上均质好的溶液加入，然后加入香精和聚丙烯酰胺，最后加入野菊花萃取物。63℃以下7000rpm均质3分钟，进行2次硫化，冷却至25℃，脱硫，过滤，即得乳白色膏霜。
可硫化稳定度如图16所示，变味-采用与原有香味相同的香，变色、悬浮度变化-冷藏及45度进行比较，在各个温度范围内无法观察到分离、黏度下降、变味、变色等情况，具有良好得稳定度。
通过以上的试验表明，野菊花萃取物具有显著的细胞再生功能，能提高人体胶原蛋白的合成，具有很强的吸收紫外光线的功能，并且与饱和油脂、非离子表面活性剂等具有很好的配伍稳定性。因此，本发明野菊花萃取物能广泛的应用于抗衰老，改善皮肤皱纹化妆品领域。野菊花萃取物在化妆品中用量可以占整个化妆品配方重量的0.0001～90％，做成营养化妆水、膏霜、精华液等。
本发明在野菊花活性物，具有显著的促进细胞再生，合成胶原蛋白的抗衰老功效，同时稳定性好。野菊花萃取物可以应用于营养化妆水、膏霜、精华液等化妆品中，在皮肤上应用具有良好的效果。
Claims (5)
1、野菊花萃取物，是这样制成的：取野菊花与水的重量比例为1：20，将野菊花切碎后加入水中，加热至90-110℃，保持该温度连续煮1.5-3个小时，过滤去除残渣后，滤液在60℃条件下减压浓缩至原来水体积的十分之一，即得具有活性成分的野菊花萃取物。
2、如权利要求1所述的野菊花萃取物，其特征在于：所述的野菊花萃取物制得的优选方案是：取野菊花与水的重量比例为1：20，将野菊花切碎后加入水中，加热至100℃，保持该温度连续煮2个小时，过滤去除残渣后，滤液在60℃条件下减压浓缩至原来水体积的十分之一，即得具有活性成分的野菊花萃取物。
3、如权利要求1或2所述的野菊花萃取物，其特征在于：所述野菊花萃取物作为有效活性成分在抗衰老、改善皮肤皱纹的功能性化妆品中应用。
4、如权利要求3所述的野菊花萃取物，其特征在于：所述的野菊花萃取物在化妆品中用量可以占整个化妆品重量的0.0001～90％。
5、如权利要求4所述的野菊花萃取物，其特征在于：所述的野菊花萃取物制成营养化妆水、膏霜、精华液及可溶化剂型的柔软化妆水构成的产品作为特点的化妆品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100907850A CN101433509A (zh) | 2008-03-28 | 2008-03-28 | 野菊花萃取物及其在抗皮肤老化化妆品中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100907850A CN101433509A (zh) | 2008-03-28 | 2008-03-28 | 野菊花萃取物及其在抗皮肤老化化妆品中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101433509A true CN101433509A (zh) | 2009-05-20 |
Family
ID=40708251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100907850A Pending CN101433509A (zh) | 2008-03-28 | 2008-03-28 | 野菊花萃取物及其在抗皮肤老化化妆品中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101433509A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102091014A (zh) * | 2010-09-08 | 2011-06-15 | 成进学 | 强化纳米元素中药负离子远红外功效性香水 |
| CN102091012A (zh) * | 2010-09-08 | 2011-06-15 | 成进学 | 蛇类纳米元素负离子远红外功效性化妆水 |
| CN103945855A (zh) * | 2011-11-23 | 2014-07-23 | 株式会社爱茉莉太平洋 | 含有白甘菊提取物的皮肤外用剂组合物 |
| KR101550578B1 (ko) * | 2013-03-05 | 2015-09-07 | 호서대학교 산학협력단 | 산국 에센셜 오일을 유효성분으로 함유하는 피부 재생용 화장료 및 피부 외용제 조성물 |
-
2008
- 2008-03-28 CN CNA2008100907850A patent/CN101433509A/zh active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102091014A (zh) * | 2010-09-08 | 2011-06-15 | 成进学 | 强化纳米元素中药负离子远红外功效性香水 |
| CN102091012A (zh) * | 2010-09-08 | 2011-06-15 | 成进学 | 蛇类纳米元素负离子远红外功效性化妆水 |
| CN102091012B (zh) * | 2010-09-08 | 2013-01-30 | 成进学 | 蛇类纳米元素负离子远红外功效性化妆水 |
| CN103945855A (zh) * | 2011-11-23 | 2014-07-23 | 株式会社爱茉莉太平洋 | 含有白甘菊提取物的皮肤外用剂组合物 |
| CN103945855B (zh) * | 2011-11-23 | 2018-04-06 | 株式会社爱茉莉太平洋 | 含有白甘菊提取物的皮肤外用剂组合物 |
| KR101550578B1 (ko) * | 2013-03-05 | 2015-09-07 | 호서대학교 산학협력단 | 산국 에센셜 오일을 유효성분으로 함유하는 피부 재생용 화장료 및 피부 외용제 조성물 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102257524B1 (ko) | 피부 진정 및 재생효과를 지니는 병풀 유래 엑소좀 함유 피부 개선용 화장료 조성물 | |
| ES2670646T3 (es) | Utilización de un extracto de lino procedente de la hidrólisis de las proteínas de lino, como agente activo antimicrobiano | |
| CN113599319A (zh) | 一种婴幼儿多效护理化妆品组合物 | |
| HK1245631A1 (zh) | 柔毛肖乳香的水醇提取物、包含其的化妝品組合物及其美容用途 | |
| US12303587B2 (en) | Extract of Moringa peregrina seed cake, method for obtaining same and use thereof in cosmetic or nutricosmetic compositions | |
| CN101664370B (zh) | 谷精草提取物及其在化妆品中的应用 | |
| CN101433509A (zh) | 野菊花萃取物及其在抗皮肤老化化妆品中的应用 | |
| KR102063686B1 (ko) | 콩뿌리 추출물을 함유하는 피부 외용제 조성물 | |
| KR100431076B1 (ko) | 천연 혼합 추출물을 함유하는 아토피 피부의 치유개선효과를 갖는 화장료 | |
| US11717476B2 (en) | Moringa peregrina seed extract rich in 2,5-diformylfuran, process for obtaining same and use thereof in cosmetic compositions | |
| FR3029417A1 (fr) | Complexe actif pour un produit cosmetique contre le vieillissement cutane | |
| EP1819352B1 (en) | Pharmaceutical compositions from carapa guianensis | |
| KR102552616B1 (ko) | 아토피 등 극건성 피부의 보습과 진정, 피부장벽강화 효과를 지니는 흰민들레 태좌 배양 추출물 함유 피부개선용 화장료 조성물 | |
| Utari et al. | Evaluation and Antibacterial Activity Test of Peel-off Mask Preparation from Combination of Pegagan Leaves (Centella asiatica (L) Urb.) and Charcoal Powder | |
| WO2000019973A1 (de) | Verwendung eines boldo-extrakts in einem kosmetischen oder dermatologischen erzeugnis | |
| KR101985660B1 (ko) | 누룩으로 발효시킨 복합생약추출물을 포함하는 여드름 개선용 화장료 조성물 | |
| CN107616936B (zh) | 抗敏修复组合物及其应用 | |
| KR101404460B1 (ko) | 어류 추출물을 포함하는 화장료 조성물 | |
| KR20100042616A (ko) | 아토피 피부에 치료 효과를 가지는 화장료 조성물 | |
| Gunarti et al. | Preparation of Ethanol Extract of Guava Leaves (Psidium Guajava L) as an Anti-Acne | |
| TWI838291B (zh) | 小葉冷水麻萃取物用以製備抗發炎的製劑的用途 | |
| JP2006056902A (ja) | 幹細胞因子の産生・放出の抑制による掻痒、肌荒れ、敏感肌及び美白用薬剤 | |
| KR102648506B1 (ko) | 맹그로브 뿌리 및 구아바 잎 추출물을 함유하는 화장료 조성물 | |
| JP7708668B2 (ja) | バラ（Ｒｏｓａ）属に属する植物から選択された分裂組織細胞株のフィトコンプレックス及び抽出物 | |
| Lamichhane | FORMULATION AND EVALUATION OF MOISTURIZING CREAM & SERUM ENRICHED WITH Apis mellifera HONEY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU HUANYA COSMETICS TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: GUANGZHOU NABION COSMETIC CO., LTD. Effective date: 20101119 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510630 NO. 15, KELIN ROAD, GUANGZHOU SCIENCE CITY, GUANGZHOU NEW + HIGH TECHNOLOGY INDUSTRY DEVELOPMENT ZONE, GUANGZHOU CITY, GUANGDONG PROVINCE TO: 510630 NO. 15, KELIN ROAD, SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY, GUANGDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20101119 Address after: 510630 Guangdong city of Guangzhou province Luogang District Science City No. 15 Ke Lin Lu Applicant after: Guangzhou Huanya Cosmetics Technology Co., Ltd. Address before: Guangzhou Science City in Guangdong province Guangzhou city 510630 Ke Lin Lu Guangzhou high tech Industrial Development Zone No. 15 Applicant before: Guangzhou Nabion Cosmetic Co., Ltd. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090520 |